Hibiki Path Advisors (“Hibiki” or “We”), a value-oriented engagement investor, sent our formal letter to the board of IHARA SCIENCE CORPORATION (5999) on 16 February 2023 regarding its recently announced MBO (Management Buy-Out) transaction.

This document does not constitute an offer, recommendation or solicitation to buy or sell any security or enter into any other transaction. Hibiki does not purport to provide any investment, financial, legal or other expert advice or recommendation in this document.

Letter to IHARA SCIENCE CORPORATION　BUSINESS WIRE press release

【Recent Posts】（Only in Japanese）
24/Jun/2022 – IHARA SCIENCE CORPORATION General Meeting of Shareholders
13/May/2022 – IHARA SCIENCE CORPORATION Comment of the financial results FY2022
19/Apr/2022 – IHARA SCIENCE CORPORATION Financial comparison with Parker Hannifin Corporation